← Back to headlines
Kyverna Therapeutics Reports Q4 GAAP EPS of -$0.80, Beating Estimates
Kyverna Therapeutics announced its financial results, reporting a GAAP Earnings Per Share (EPS) of -$0.80, which surpassed analyst estimates by $0.05.
26 Mar, 20:36 — 26 Mar, 20:36
Sources
Showing 1 of 1 sources
